TY - JOUR A1 - Bünder, Tobias A1 - Rathert, Nikolas A1 - Mair, Johanna T1 - Sustaining the Integration of Social Objectives Over Time: A Case-Based Analysis of Access to Medicine in the Pharmaceutical Industry JF - Business & Society N2 - Companies increasingly seek to strategically integrate social objectives in commercial activities to address societal challenges, yet little is known about how companies can sustain such a commitment over time. To address this question, we conduct a case-based, abductive study of two pharmaceutical companies widely considered industry leaders in facilitating access to medicine over a 20-year period (2000–2019). We identify product and operation-level integration as distinct types of integration efforts enacted by these companies. Tracing the intraorganizational dynamics associated with these efforts, we theorize that sustained integration is contingent on companies’ ability to respond to and address the challenges specific to product and operation-level integration. The theoretical framework we develop contributes to an emerging debate on the potential of companies to make progress on societal challenges by strategically integrating social objectives, including but not limited to those related to global health. Y1 - 2023 U6 - https://doi.org/10.1177/00076503231182667 N1 - Open Access publication is funded by the Hertie School Library ER - TY - CHAP A1 - Bünder, Tobias A1 - Rathert, Nikolas A1 - Mair, Johanna ED - George, Gerard ED - Haas, Martine ED - Joshi, Havovi ED - McGahan, Anita ED - Tracey, Paul T1 - Understanding firm- and field-level change toward sustainable development: insights from the pharmaceutical industry and access to medicines, 1960‒2020 T2 - Handbook on the Business of Sustainability N2 - Insufficient access to medicines is a persistent global problem that affects billions of people in low- and middle-income countries. In this chapter, we use access to medicines as a case to understand how business can become instrumental in making progress on persistent and global problems we associate with sustainable development. We examine the emergence and evolution of access to medicines as a mandate for the pharmaceutical industry to contribute to sustainable development. More specifically, we trace the historical developments of corporate social initiatives in the industry and revisit existing research on access to medicines in management and related fields. We then introduce three distinct analytical perspectives - field emergence and change, firm heterogeneity, organizational processes - to examine access to medicine, expose managerial challenges and offer a research agenda that helps to advance research on access to medicines and, more generally, on corporate efforts to address pressing global problems subsumed under the Sustainable Development Goals. Y1 - 2022 SN - 9781839105333 U6 - https://doi.org/10.4337/9781839105340.00025 SP - 300 EP - 319 PB - Edward Elgar CY - Cheltenham ER -